Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.780
+0.040 (2.30%)
At close: Nov 1, 2024, 4:00 PM
1.740
-0.040 (-2.25%)
After-hours: Nov 1, 2024, 6:59 PM EDT
Heron Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Heron Therapeutics stock have an average target of 6.00, with a low estimate of 5.00 and a high estimate of 7.00. The average target predicts an increase of 237.08% from the current stock price of 1.78.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 25, 2024.
Analyst Ratings
The average analyst rating for HRTX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +180.90% | Sep 25, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +180.90% | Aug 7, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +293.26% | Jun 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +180.90% | May 16, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +180.90% | May 8, 2024 |
Financial Forecast
Revenue This Year
150.50M
from 127.04M
Increased by 18.46%
Revenue Next Year
182.99M
from 150.50M
Increased by 21.59%
EPS This Year
-0.12
from -0.80
EPS Next Year
0.01
from -0.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 160.1M | 193.1M | 233.6M | ||
| Avg | 150.5M | 183.0M | 222.5M | ||
| Low | 141.2M | 171.5M | 208.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.0% | 28.3% | 27.7% | ||
| Avg | 18.5% | 21.6% | 21.6% | ||
| Low | 11.2% | 14.0% | 14.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.08 | 0.03 | 0.28 | ||
| Avg | -0.12 | 0.01 | 0.23 | ||
| Low | -0.16 | -0.05 | 0.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 3,971.9% | ||
| Avg | - | - | 3,193.8% | ||
| Low | - | - | 2,746.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.